Characteristics of eligible patients according to treatment group
| . | Total (n = 383), no. (%) . | SD-DN arm (n = 189), no. (%) . | HD-DN arm (n = 194), no. (%) . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 206 (53.8) | 90 (47.6) | 116 (59.8) | .017 |
| Female | 177 (46.2) | 99 (52.4) | 78 (40.2) | |
| Age, y | ||||
| ≤ 40 | 160 (41.8) | 73 (38.6) | 87 (44.8) | .217 |
| > 40 | 223 (58.2) | 116 (61.4) | 107 (55.2) | |
| Leukemia | ||||
| De novo | 366 (95.6) | 183 (96.8) | 183 (94.3) | .236 |
| Secondary | 17 (4.4) | 6 (3.2) | 11 (5.7) | |
| Karnofsky performance score | ||||
| ≥ 90 | 311 (81.2) | 151 (19.9) | 160 (82.5) | .518 |
| < 90 | 72 (18.8) | 38 (20.1) | 34 (17.5) | |
| Hemoglobin, g/dL | ||||
| < 8.0 | 160 (41.8) | 82 (43.4) | 78 (40.2) | .528 |
| ≥ 8.0 | 223 (58.2) | 107 (56.6) | 116 (59.8) | |
| WBC at diagnosis, /μL | ||||
| < 50 000 | 295 (77.0) | 148 (78.3) | 147 (75.8) | .556 |
| ≥ 50 000 | 88 (23.0) | 41 (21.7) | 47 (24.2) | |
| Uric acid, mg/dL* | ||||
| < 7.0 | 332 (88.8) | 167 (90.3) | 166 (87.4) | .373 |
| ≥ 7.0 | 42 (11.2) | 18 (9.7) | 24 (12.6) | |
| LDH† | ||||
| Normal | 57 (14.9) | 24 (14.8) | 33 (19.4) | .267 |
| Elevated | 275 (71.8) | 138 (85.2) | 137 (80.6) | |
| Cytogenetic risk group | ||||
| Good | 81 (21.1) | 36 (19.0) | 45 (23.2) | .523 |
| Intermediate | 239 (62.4) | 123 (65.1) | 116 (59.8) | |
| Poor | 57 (14.9) | 26 (13.8) | 31 (16.0) | |
| Unknown | 6 (1.6) | 4 (2.1) | 2 (1.0) |
| . | Total (n = 383), no. (%) . | SD-DN arm (n = 189), no. (%) . | HD-DN arm (n = 194), no. (%) . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 206 (53.8) | 90 (47.6) | 116 (59.8) | .017 |
| Female | 177 (46.2) | 99 (52.4) | 78 (40.2) | |
| Age, y | ||||
| ≤ 40 | 160 (41.8) | 73 (38.6) | 87 (44.8) | .217 |
| > 40 | 223 (58.2) | 116 (61.4) | 107 (55.2) | |
| Leukemia | ||||
| De novo | 366 (95.6) | 183 (96.8) | 183 (94.3) | .236 |
| Secondary | 17 (4.4) | 6 (3.2) | 11 (5.7) | |
| Karnofsky performance score | ||||
| ≥ 90 | 311 (81.2) | 151 (19.9) | 160 (82.5) | .518 |
| < 90 | 72 (18.8) | 38 (20.1) | 34 (17.5) | |
| Hemoglobin, g/dL | ||||
| < 8.0 | 160 (41.8) | 82 (43.4) | 78 (40.2) | .528 |
| ≥ 8.0 | 223 (58.2) | 107 (56.6) | 116 (59.8) | |
| WBC at diagnosis, /μL | ||||
| < 50 000 | 295 (77.0) | 148 (78.3) | 147 (75.8) | .556 |
| ≥ 50 000 | 88 (23.0) | 41 (21.7) | 47 (24.2) | |
| Uric acid, mg/dL* | ||||
| < 7.0 | 332 (88.8) | 167 (90.3) | 166 (87.4) | .373 |
| ≥ 7.0 | 42 (11.2) | 18 (9.7) | 24 (12.6) | |
| LDH† | ||||
| Normal | 57 (14.9) | 24 (14.8) | 33 (19.4) | .267 |
| Elevated | 275 (71.8) | 138 (85.2) | 137 (80.6) | |
| Cytogenetic risk group | ||||
| Good | 81 (21.1) | 36 (19.0) | 45 (23.2) | .523 |
| Intermediate | 239 (62.4) | 123 (65.1) | 116 (59.8) | |
| Poor | 57 (14.9) | 26 (13.8) | 31 (16.0) | |
| Unknown | 6 (1.6) | 4 (2.1) | 2 (1.0) |